fda semaglutide compounding enforcement november 2025 Novo Nordisk expands legal action to protect US patients from unsafe, non- FDA-approved compounded "semaglutide" GLP-1s: Life after FDA enforcement

Retatrutides triple-action approach addresses this challenge head-on

The low-dose (0.03 mg/kg), medium-dose (0.1 mg/kg), and high-dose (0.33 mg/kg) groups lost 2 g, 4 g, and 1 g of weight after 8 weeks

We serve clients from Northridge CA, Los Angeles CA, West LA, Porter Ranch CA, San Fernando CA, Calabasas CA, Woodland Hills CA, Hidden Hills CA, Granada Hills, and BEYOND

We work with you through telehealth to build a plan that fits your life, your goals, and your budget

To bolster its analysis, the FDA also looked at healthcare claims data from its Sentinel Systema national electronic database that monitors the safety of approved productsto compare suicidality between GLP-1s and sodium-glucose cotransporter 2 inhibitors, a popular drug class for treating type 2 diabetes